Comparison of NGS and MFC methods

• Verfasst von: Kriegsmann, Katharina [VerfasserIn]
• Verfasst von: Hundemer, Michael [VerfasserIn]
• Verfasst von: Hofmeister-Mielke, Nicole [VerfasserIn]
• Verfasst von: Reichert, Philipp [VerfasserIn]
• Verfasst von: Manta, Calin-Petru [VerfasserIn]
• Verfasst von: Awwad, Mohamed [VerfasserIn]
• Verfasst von: Sauer, Sandra [VerfasserIn]
• Verfasst von: Bertsch, Uta [VerfasserIn]
• Verfasst von: Besemer, Britta [VerfasserIn]
• Verfasst von: Fenk, Roland [VerfasserIn]
• Verfasst von: Hänel, Mathias [VerfasserIn]
• Verfasst von: Munder, Markus [VerfasserIn]
• Verfasst von: Weisel, Katja C. [VerfasserIn]
• Verfasst von: Blau, Igor-Wolfgang [VerfasserIn]
• Verfasst von: Neubauer, Andreas [VerfasserIn]
• Verfasst von: Müller-Tidow, Carsten [VerfasserIn]
• Verfasst von: Raab, Marc-Steffen [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Huhn, Stefanie [VerfasserIn]
• Titel: Comparison of NGS and MFC methods
• Titelzusatz: key metrics in multiple myeloma MRD assessment
• Verf.angabe: Katharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, Philipp Reichert, Calin-Petru Manta, Mohamed H. S. Awwad, Sandra Sauer, Uta Bertsch, Britta Besemer, Roland Fenk, Mathias Hänel, Markus Munder, Katja C. Weisel, Igor W. Blau, Andreas Neubauer, Carsten Müller-Tidow, Marc S. Raab, Hartmut Goldschmidt, Stefanie Huhn and for the German-speaking Myeloma Multicenter Group (GMMG)
• E-Jahr: 2020
• Jahr: 18 August 2020
• Umfang: 15 S.
• Fussnoten: Gesehen am 04.01.2021
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2020
• Band/Heft Quelle: 12(2020,8) Artikel-Nummer 2322, 15 Seiten
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers12082322
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: EuroFlow
• Sach-SW: minimal residual disease (MRD)
• Sach-SW: multicolor flow cytometry (MFC)
• Sach-SW: multiple myeloma (MM)
• Sach-SW: next-generation sequencing (NGS)
• K10plus-PPN: 1743772130

Abstract

In order to meet the challenges in data evaluation and comparability between studies in multiple myeloma (MM) minimal residual disease (MRD) assessment, the goal of the current study was to provide a step-by-step evaluation of next-generation sequencing (NGS) and multicolor flow cytometry (MFC) data. Bone marrow (BM) sample pairs from 125 MM patients were analyzed by NGS and MFC MM MRD methods. Tumor load (TL) and limit of detection (LOD) and quantification (LOQ) were calculated. The best-fit MRD cut-off was chosen as 1 × 10−5, resulting in an overall 9.6% (n overall = 12 (NGS n = 2, MFC n = 10)) nonassessable cases. The overall concordance rate between NGS and MFC was 68.0% (n = 85); discordant results were found in 22.4% (11.2% (n = 14) of cases in each direction. Overall, 55.1% (n = 60/109) and 49.5% (n = 54/109) of patients with a serological response ≥ very good partial response (VGPR) showed BM MRD negativity by NGS and MFC, respectively. A good correlation in the TL assessed by both techniques was found (correlation coefficient = 0.8, n = 40, p < 0.001). Overall, our study shows good concordance between MM BM MRD status and TL when comparing NGS and MFC at a threshold of 10–5. However, a sufficient number of analyzed events and calculation of MRD key metrics are essential for the comparison of methods and evaluability of data at a specific MRD cut-off.